Drugs for Eating Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 201)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Zinc cation |
Approved, Experimental, Investigational |
Phase 4 |
|
7440-66-6, 23713-49-7 |
32051 |
Synonyms:
alpha D Mannosidase
alpha D Mannoside mannohydrolase
alpha Mannosidase
alpha Mannosidase b
alpha-D-Mannosidase
alpha-D-Mannoside mannohydrolase
alpha-Mannosidase
alpha-Mannosidase, lysosomal
alpha-Mannosidase, neutral
Dietary zinc
LAMAN
Lysosomal alpha mannosidase
Lysosomal alpha-mannosidase
Mannohydrolase, alpha-D-mannoside
Mannosidase b, alpha
Neutral alpha mannosidase
|
Neutral alpha-mannosidase
Topostin b
Zinc cation
ZINC ion
Zinc ion(2+)
Zinc(2+)
Zinc(II)
Zinc, chelated
Zinc, elemental
Zinc, ion (ZN2+)
zinc|zinc ion
Zincum metallicum
Zn
ZN(2+)
ZN(II)
ZN2+
|
|
2 |
|
Zinc sulfate |
Approved, Investigational |
Phase 4 |
|
7733-02-0 |
|
Synonyms:
Zinc sulfate (anhydrous)
Zinc sulfate anhydrous
Zinc sulfate, anhydrous
|
Zinc sulphate
Zinc sulphate anhydrous
Zinc sulphate, anhydrous
|
|
3 |
|
Dextroamphetamine |
Approved, Illicit, Investigational |
Phase 4 |
|
51-64-9, 300-62-9 |
5826 3007 |
Synonyms:
(±)-amphetamine|Amphetamine Sulfate®|DL-amphetamine
(+)-(S)-Amphetamine
(+)-alpha-Methylphenethylamine
(+)-alpha-Methylphenylethylamine
(+-)-alpha-Methylphenylethylamine
(+)-alpha-methylphenylethylamine|d-amphetamine|Dexadrine®|dextroamphetamine|Dextrostat®|S(+)amphetamine
(+)-a-Methylphenethylamine
(+)-a-Methylphenylethylamine
(+)-Amphetamine
(+)-phenaminum
(+)-Α-methylphenethylamine
(+)-Α-methylphenylethylamine
(+/-)-benzedrine
(+/-)-beta-phenylisopropylamine
(+/-)-desoxynorephedrine
(2S)-(+)-Amphetamine
(2S)-1-phenylpropan-2-amine
(AlphaS)-alpha-methylbenzeneethanamine
(AlphaS)-a-methylbenzeneethanamine
(AlphaS)-α-methylbenzeneethanamine
(S)-(+)-Amphetamine
(S)-(+)-beta-Phenylisopropylamine
(S)-(+)-b-Phenylisopropylamine
(S)-(+)-Β-phenylisopropylamine
(S)-1-Phenyl-2-aminopropane
(S)-1-Phenyl-2-propanamine
(S)-1-Phenyl-2-propylamine
(S)-alpha-Methylbenzeneethanamine
(s)-alpha-methylphenethylamine
(s)-alpha-phenylethylamine
(S)-a-Methylbenzeneethanamine
(S)-Amphetamine
(S)-Α-methylbenzeneethanamine
(αS)-α-methylbenzeneethanamine
[1-(3-Methoxyphenyl)-2-propyl]amine
1-Methyl-2-phenylethylamine
1-Phenyl-2-aminopropane
3-Methoxy-a-methylbenzeneethanamine
3-Methoxyamphetamine
3-Methoxyphenylisopropylamine
Actedron
Adipan
Adzenys
ADZENYS ER
ADZENYS XR-ODT
Allodene
alpha-Methylbenzeneethaneamine
Amfetamin
Amfetamina
Amfetamine
Amfetaminum
Amphetamine
AMPHETAMINE RESIN COMPLEX
Amphetamine sulfate
Amphetamine sulfate (2:1)
Amsustain
Anorexide
Anorexine
Benzebar
Benzedrine
Benzolone
beta-Aminopropylbenzene
beta-Phenylisopropylamin
beta-Phenyl-isopropylamine
Celltech brand OF dextroamphetamine sulfate
Centramina
Curban
D Amphetamine
D Amphetamine sulfate
D-(+)-amphetamine
D-(s)-amphetamine
D-1-Phenyl-2-aminopropan
d-1-Phenyl-2-aminopropan [German]
D-1-Phenyl-2-aminopropane
D-2-Amino-1-phenylpropane
D-alpha-methylphenethylamine
D-am
D-Amphetamine
D-Amphetamine sulfate
Dephadren
Desamfetamina
Desoxyn
Desoxynorephedrin
Desoxynorephedrine
Dexacaps
Dexadrine
Dexamfetamina
|
Dexamfetamina [inn-spanish]
Dexamfetamine
Dexamfetaminum
Dexamfetaminum [inn-latin]
DEXAMPEX
Dexamphetamine
Dexamphetaminum [inn-latin]
Dexanfetamina
Dexanfetamina [inn-spanish]
Dexedrine
Dexedrine Spansule
Dexidrine
Dextro amphetamine
Dextro amphetamine sulfate
Dextroamphetamine
Dextro-amphetamine
DEXTROAMPHETAMINE RESIN COMPLEX
Dextroamphetamine sulfate
Dextro-amphetamine sulfate
DextroStat
DL-1-Phenyl-2-aminopropane
DL-alpha-Methylphenethylamine
DL-Amphetamine
DL-Benzedrine
Dyanavel
DYANAVEL XR
Elastonon
Fenamin
Fenamine
Fenylo-izopropylaminyl
FERNDEX
Finam
GlaxoSmithKline brand OF dextroamphetamine sulfate
Isoamycin
Isoamyne
Isomyn
L Amphetamine
L-Amphetamine
Levo amphetamine
Levoamphetamine
Levo-amphetamine
Mallinckrodt brand OF dextroamphetamine sulfate
Mecodrin
Methampex
Methamphetamine HCL
Miquel brand OF amfetamine sulfate
m-Methoxy-a-methylphenethylamine
m-Methoxyamphetamine
Mydrial
Norephedrane
Novydrine
NSC-27159
NSC-73713
Oktedrin
Ortedrine
Oxydess
Paredrine
Pasadena brand OF dextroamphetamine
Percomon
Phenamine
Phenedrine
Phenopromin
Phenylisopropylamine
Profamina
Propisamine
Psychedrine
rac-(2R)-1-phenylpropan-2-amine
rac-amphetamine
Raphetamine
Rhinalator
S(+)-amphetamine
Shire brand OF dextroamphetamine sulfate
Simpatedrin
Simpatina
Sulfate, amphetamine
Sulfate, dextroamphetamine
Sympamin
Sympamine
Sympatedrine
Thyramine
Vortech brand OF dextroamphetamine sulfate
Weckamine
α-methylbenzeneethaneamine
α-methylphenethylamine
β-aminopropylbenzene
β-phenylisopropylamine
|
|
4 |
|
Levoleucovorin |
Approved, Experimental, Investigational |
Phase 4 |
|
68538-85-2, 58-05-9, 73951-54-9 |
149436 6006 |
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R)-Leucovorin
(6R,2'S)-Folinic acid
(6R,S)-5-Formyltetrahydrofolate
(6S)-5-Formyl-5,6,7,8-tetrahydrofolate
(6S)-5-FORMYL-5,6,7,8-TETRAHYDROFOLIC ACID
(6S)-5-Formyltetrahydrofolate
(6S)-5-FORMYLTETRAHYDROFOLIC ACID
(6S)-Folinate
(6S)-FOLINIC ACID
(6S)-LEUCOVORIN
(S)-LEUCOVORIN
[6R]-5-formyl-5,6,7,8-tetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formlyl-5,6,7,8-tetrahydrofolate,calcium salt
5-Formyl-(6S)-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formylTHF
6 S Leucovorin
6R-Leucovorin
6S Leucovorin
6S-Leucovorin
6-S-Leucovorin
Acid, folinic
Acide folinique
Acido folinico
ácido levofolínico
Calcium citrovorum factor
Calcium folinate
Calcium leucovorin
CF
Citrovorum factor
Dextrofolinic acid
Factor, citrovorum
Folinate
Folinate, calcium
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid SF
Folinic acid-SF
FUSILEV
KHAPZORY
|
Kunyrin
L(-)-5-Formyl-5,6,7,8-tetrahydrofolate
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
Leucal
Leucoverin
Leucovorin
Leucovorin calcium
Leucovorin folinic acid
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, (S)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, (S)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monopotassium salt, (S)-isomer
Leucovorin, monosodium salt
Leucovorin, monosodium salt, (S)-isomer
Leucovorinum
Leukovorin
Leukovorum
Levo leucovorin
LEVOFOLENE
Levofolinate
LEVOFOLINIC ACID
Levoleucovorin
Levo-leucovorin
L-Folinate
L-FOLINIC ACID
LFP-754
L-Leucovorin
L-N-[P-[[(2-amino-5-Formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-glutamic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamate
N-[4-({[(6S)-2-AMINO-5-FORMYL-4-OXO-1,4,5,6,7,8-HEXAHYDROPTERIDIN-6-YL]METHYL}AMINO)BENZOYL]-L-GLUTAMIC ACID
N-{[4-({[(6R)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]carbonyl}-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
N5-Formyl-THF
Pteroyl-D-glutamate
Rescuvolin
S Leucovorin
S-Leucovorin
Welcovorin
Wellcovorin
|
|
5 |
|
Fluoxetine |
Approved, Vet_approved |
Phase 4 |
|
54910-89-3 |
3386 |
Synonyms:
(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-P-tolyl)oxy)propylamine
(+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
Adofen
Animex-On
Deprex
Eufor
Fluctin
Fluoxeren
Fluoxetin
Fluoxetina
Fluoxetina [INN-Spanish]
Fluoxetina [Spanish]
FLUOXETINE
Fluoxétine
Fluoxetine Hcl
Fluoxetine hydrochloride
|
Fluoxetinum
Fluoxetinum [INN-Latin]
Fluval
Fontex
Foxetin
N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
NSC-283480
Portal
Prozac
Prozac Weekly
Prozac®
Pulvules
Reneuron
Sarafem
Symbyax
|
|
6 |
|
Aripiprazole |
Approved, Investigational |
Phase 4 |
|
129722-12-9 |
60795 |
Synonyms:
7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone
Abilify
ABILIFY MAINTENA
ABILIFY MAINTENA KIT
ABILIFY MYCITE KIT
Abilify®|Aripiprex®|Aristada® (aripiprazole lauroxil)|OPC 14597|OPC-14597
Abilitat
Aripiprazol
|
ARIPIPRAZOLE
Aripiprazolum
ARIPIPREX
OPC 14597
OPC 31
OPC-14597
OPC-31
|
|
7 |
|
Orlistat |
Approved, Investigational |
Phase 4 |
|
96829-58-2 |
3034010 |
Synonyms:
(-)-Tetrahydrolipostatin
(-)-Tetrahydrolipstatin
(2S)-2-Formamido-4-methylpentanoate [(2S)-1-[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]tridecan-2-yl] ester
(2S)-2-Formamido-4-methylpentanoic acid [(2S)-1-[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]tridecan-2-yl] ester
1-((3-Hexyl-4-oxo-2-oxetanyl)methyl)dodecyl-2-formamido-4-methylvalerate
Alli
Alli®|tetrahydrolipstatin|THL|Xenical®
BEACITA
GlaxoSmithKline brand OF orlistat
Hoffmann-la roche brand OF orlistat
LIPSTATIN
N-Formyl-L-leucine (1S)-1-{[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl}dodecyl ester
Orlipastat
|
ORLIPASTATUM
ORLISTAT
Orlistatum
Ro-18-0647
RO-180647002
RO-180647-002
Roche brand OF orlistat
Tetrahydrolipastatin
Tetrahydrolipstatin
THL
THLP
Xenical
|
|
8 |
|
Baclofen |
Approved |
Phase 4 |
|
1134-47-0 |
2284 |
Synonyms:
(+-)-Baclofen
4-Amino-3-(4-chlorophenyl)butyrate
4-Amino-3-(4-chlorophenyl)butyric acid
Alphapharm brand OF baclofen
apo Baclofen
apo-Baclofen
ApoBaclofen
Apotex brand OF baclofen
Ashbourne brand OF baclofen
ASTA medica brand OF baclofen
Athena brand OF baclofen
Atrofen
AWD, baclofen
b-(4-Chlorophenyl)gaba
b-(Aminomethyl)-4-chlorobenzenepropanoate
b-(Aminomethyl)-4-chlorobenzenepropanoic acid
b-(Aminomethyl)-p-chlorohydrocinnamate
b-(Aminomethyl)-p-chlorohydrocinnamic acid
b-(p-Chlorophenyl)-g-aminobutyrate
b-(p-Chlorophenyl)-g-aminobutyric acid
BA-34647
BACLOFEN
Baclofen alphapharm brand
Baclofen apotex brand
Baclofen ashbourne brand
Baclofen athena brand
Baclofen awd
Baclofen ciba-geigy brand
Baclofen irex brand
Baclofen isis brand
Baclofen medtronic brand
Baclofen novartis brand
Baclofen nu-pharm brand
Baclofen pharmascience brand
Baclofene
Baclofène
Baclofène irex
Baclofène-irex
BaclofèneIrex
Baclofeno
Baclofenum
Baclon®|Kemstro®|Lioresal®
Baclophen
Baclospas
BACLOSPAS-10
beta-(4-Chlorophenyl)gaba
beta-(Aminomethyl)-4-chlorobenzenepropanoate
beta-(Aminomethyl)-4-chlorobenzenepropanoic acid
beta-(Aminomethyl)-p-chlorohydrocinnamate
beta-(Aminomethyl)-p-chlorohydrocinnamic acid
|
beta-(p-Chlorophenyl)-gamma-aminobutyrate
beta-(p-Chlorophenyl)-gamma-aminobutyric acid
Chlorophenyl gaba
Ciba geigy brand OF baclofen
CIBA34,647ba
CIBA-34,647-ba
Ciba-geigy brand OF baclofen
Clofen
DL-4-Amino-3-p-chlorophenylbutanoate
DL-4-Amino-3-p-chlorophenylbutanoic acid
DL-Baclofen
GABA, chlorophenyl
GABLOFEN
g-Amino-b-(p-chlorophenyl)butyrate
g-Amino-b-(p-chlorophenyl)butyric acid
gamma-Amino-beta-(p-chlorophenyl)butyrate
gamma-Amino-beta-(p-chlorophenyl)butyric acid
Gen baclofen
Gen-baclofen
GenBaclofen
Genpharm
Irex brand OF baclofen
Isis brand OF baclofen
Kemstro
Lebic
Lioresal
LIORESAL INTRATH
LYFLEX
Medtronic brand OF baclofen
Novartis brand OF baclofen
Nu baclo
Nu pharm brand OF baclofen
Nu-baclo
NuBaclo
Nu-pharm brand OF baclofen
PCP-GABA
Pharmascience brand OF baclofen
PMS Baclofen
PMSBaclofen
PMS-Baclofen
Β-(4-chlorophenyl)gaba
Β-(aminomethyl)-4-chlorobenzenepropanoate
Β-(aminomethyl)-4-chlorobenzenepropanoic acid
Β-(aminomethyl)-p-chlorohydrocinnamate
Β-(aminomethyl)-p-chlorohydrocinnamic acid
Β-(p-chlorophenyl)-γ-aminobutyrate
Β-(p-chlorophenyl)-γ-aminobutyric acid
Γ-amino-β-(p-chlorophenyl)butyrate
Γ-amino-β-(p-chlorophenyl)butyric acid
|
|
9 |
|
Liraglutide |
Approved |
Phase 4 |
|
204656-20-2 |
44147092 16134956 |
Synonyms:
ARG34LYS26-(N-Ε-(Γ-GLU(N-Α-HEXADECANOYL)))-GLP-1[7-37]
LIRAGLUTIDA
LIRAGLUTIDE
Liraglutide (genetical recombination)
Liraglutide (rDNA origin)
LIRAGLUTIDE RECOMBINANT
LIRAGLUTIDUM
N²⁶-(HEXADECANOYL-GAMMA-GLUTAMYLE)-[34-ARGININE]GLP-1-(7-37)-PEPTIDE
N²⁶-(N-HEXADECANOYL-L-GAMMA-GLUTAMYL)-[34-L-ARGININE]GLUCAGON-LIKE PEPTIDE 1-(7-37)-PEPTIDE
NN 2211
|
NN2211
NN-2211
NN-2211|NN2211|Victoza®
NN9924
NN-9924
NNC 90-1170
NNC-90-1170
SAXENDA
VICTOZA
|
|
10 |
|
Sibutramine |
Approved, Illicit, Investigational, Withdrawn |
Phase 4 |
|
106650-56-0 |
5210 |
Synonyms:
(R)-DDMS
Butramin
Didesmethylsibutramine
Di-desmethylsibutramine
Medaria
Meridia
Meridia®|sibutramine hydrochloride
methylnaltrexone
mono-Desmethylsibutramine
|
N-1-(1-(4-Chlorophenyl)cyclobutyl)-3-methylbutyl-N,N-dimethylamine HCL
Reductil
SIBUTRAMINA
Sibutramina [Spanish]
SIBUTRAMINE
Sibutramine hydrochloride
SIBUTRAMINUM
Sibutraminum [Latin]
|
|
11 |
|
Duloxetine |
Approved |
Phase 4 |
|
136434-34-9, 116539-59-4 |
60835 |
Synonyms:
(+-)-duloxetine
(3S)-N-Methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine
(S)-duloxetine
ARICLAIM
Cymbalta
Cymbalta®|LY248686
DUCILTIA
Duloxetina
Duloxetine
Duloxetine ethanedioate (1:1), (+-)-isomer - T353987
Duloxetine HCL
Duloxetine hydrochloride
|
Duloxetine, (+)-isomer
HCL, Duloxetine
Hydrochloride, duloxetine
LY 248686
LY248686
LY-248686
LY248686 HCL
LY-248686 HCL
N-Methyl-3-(1-naphthalenyloxy)-2-thiophenepropanamine
N-Methyl-3-(1-naphthalenyloxy)-3-(2-thiophene)propanamide
Yentreve
|
|
12 |
|
Memantine |
Approved, Investigational |
Phase 4 |
|
41100-52-1, 19982-08-2 |
4054 |
Synonyms:
1,3-Dimethyl-5-adamantanamine
1,3-Dimethyl-5-aminoadamantane
1,3-DIMETHYLAMINOADAMANTANE
1-Amino-3,5-dimethyladamantane
3,5-Dimethyl-1-adamantanamine
3,5-Dimethyl-1-aminoadamantane
3,5-Dimethyltricyclo(3.3.1.1(3,7))decan-1-amine
AKATINOL
Axura
Axura®|Ebixa®|Namenda®
D-145
DMAA
DRG-0267
Ebixa
Exiba
FP-01
Lundbeck brand OF memantine hydrochloride
|
MARIXINO
Memantin
Memantina
Memantina [INN-Spanish]
MEMANTINE
Memantine [INN]
MEMANTINE HCL
Memantine hydrochloride
Memantinum
Memantinum [INN-Latin]
Merz brand OF memantine hydrochloride
Namenda
NAMENDA XR
NEMDATINE
NSC-102290
SUN-Y7017
VALIOS
|
|
13 |
|
Atomoxetine |
Approved |
Phase 4 |
|
82248-59-7, 83015-26-3 |
54841 |
Synonyms:
(-)-Tomoxetine
Atomoxetina
Atomoxetine
Atomoxetine HCL
Atomoxetine hydrochloride
HCL, Atomoxetine
Hydrochloride, atomoxetine
LY-139603
LY-139603|Strattera®
N-Methyl-gamma-(2-methylphenoxy)benzenepropanamine hydrochloride
Strattera
|
Tomoxetina
Tomoxetina [Spanish]
Tomoxetine
Tomoxetine [INN]
TOMOXETINE HCL
Tomoxetine hydrochloride, (-)-isomer
Tomoxetine hydrochloride, (+-)-isomer
Tomoxetine hydrochloride, (+)-isomer - T351671
Tomoxetinum
Tomoxetinum [Latin]
|
|
14 |
|
Norepinephrine |
Approved |
Phase 4 |
|
51-41-2 |
439260 |
Synonyms:
(-)-(R)-Norepinephrine
(-)-alpha-(Aminomethyl)protocatechuyl alcohol
(−)-arterenol
(-)-Arterenol
(−)-noradrenaline
(-)-Noradrenaline
(−)-norepinephrine
(-)-Norepinephrine
(-)-norepinephrine|Levarterenol®|noradrenaline
(R)-(−)-norepinephrine
(R)-(-)-Norepinephrine
(R)-4-(2-amino-1-hydroxyethyl)-1,2-benzenediol
(R)-noradrenaline
(R)-norepinephrine
4-(2-amino-1-Hydroxyethyl)-1,2-benzenediol
4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol
4-[(1R)-2-AMINO-1-HYDROXYETHYL]BENZENE-1,2-DIOL
4-[(1R)-2-AMINO-1-HYDROXY-ETHYL]BENZENE-1,2-DIOL
4-[(1R)-2-AMINO-1-HYDROXY-ETHYL]PYROCATECHOL
Adrenor
Aktamin
Arterenol
L-2-amino-1-(3,4-Dihydroxyphenyl)ethanol
|
L-3,4-Dihydroxyphenylethanolamine
L-alpha-(Aminomethyl)-3,4-dihydroxybenzyl alcohol
L-Arterenol
Levarterenol
Levoarterenol
Levonor
Levonoradrenaline
Levonorepinephrine
Levophed
L-noradrenaline
L-Norepinephrine
Noradrenalin
Noradrenaline
Nor-adrenaline
Norartrinal
Norepinefrina
Norepinephrine
Norépinéphrine
Norepinephrinum
Norepirenamine
Nor-epirenan
R-NOREPINEPHRINE
Sympathin E
|
|
15 |
|
Megestrol acetate |
Approved, Investigational, Vet_approved |
Phase 4 |
|
595-33-5 |
11683 |
Synonyms:
17-ACETOXY-6-METHYLPREGNA-4,6-DIENE-3,20-DIONE
17ALPHA-ACETOXY-6-DEHYDRO-6-METHYLPROGESTERONE
17ALPHA-HYDROXY-6-METHYLPREGNA-4,6-DIENE-3,20-DIONE ACETATE
17-HYDROXY-6-METHYLPREGNA-4,6-DIENE-3,20-DIONE 17-ACETATE
17Α-ACETOXY-6-DEHYDRO-6-METHYLPROGESTERONE
17Α-HYDROXY-6-METHYLPREGNA-4,6-DIENE-3,20-DIONE ACETATE
5071
6-DEHYDRO-6-METHYL-17ALPHA-ACETOXYPROGESTERONE
6-DEHYDRO-6-METHYL-17Α-ACETOXYPROGESTERONE
6-METHYL-17ALPHA-ACETOXYPREGNA-4,6-DIENE-3,20-DIONE
6-METHYL-17ALPHA-HYDROXY-DELTA(SUP 6)-PROGESTERONE ACETATE
6-METHYL-17Α-ACETOXYPREGNA-4,6-DIENE-3,20-DIONE
6-METHYL-17Α-HYDROXY-DELTA(SUP 6)-PROGESTERONE ACETATE
6-METHYL-6-DEHYDRO-17ALPHA-ACETOXYPROGESTERONE
6-METHYL-6-DEHYDRO-17Α-ACETOXYPROGESTERONE
6-METHYL-DELTA(SUP 4,6)-PREGNADIEN-17ALPHA-OL-3,20-DIONE ACETATE
6-METHYL-DELTA(SUP 4,6)-PREGNADIEN-17Α-OL-3,20-DIONE ACETATE
6-METHYL-DELTA(SUP 6)-DEHYDRO-17ALPHA-ACETOXYPROGESTERONE
6-METHYL-DELTA(SUP 6)-DEHYDRO-17Α-ACETOXYPROGESTERONE
|
BDH-1298
MAGESTIN
MAYGACE
MEGACE
MEGACE ES
MEGERON
MEGESTAT
MEGESTIL
MEGESTIN
MEGESTROL
MEGESTROL ACETATE
MGA
NIA
NIAGESTIN
NSC-71423
OVABAN
OVARID
SC-10363
VOLIDAN
|
|
16 |
|
Cyproheptadine |
Approved |
Phase 4 |
|
129-03-3 |
2913 |
Synonyms:
1-Methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine
1-Methyl-4-(5H-dibenzo(a,D)cycloheptenylidene)piperidine
4-(5-Dibenzo(a,D)cyclohepten-5-ylidine)-1-methylpiperidine
4-(5H-Dibenzo(a,D)cyclohepten-5-ylidene)-1-methylpiperidine
4-Dibenzo[a,D]cyclohepten-5-ylidene-1-methyl-piperidine
5-(1-Methylpiperidylidene-4)-5H-dibenzo(a,D)cyclopheptene
Antergan
AXOPROL
Ciproheptadina
Ciprovit
|
Cyproheptadin
Cyproheptadine
Cyproheptadinum
CYPROHEPTIDINE
cyproheptidine|Periactin®|Peritol®
Dihexazin
GLUTODINA
Periactin
Peritol
Viternum
|
|
17 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
Phase 4 |
|
59-30-3 |
6037 |
Synonyms:
(2S)-2-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)FORMAMIDO]PENTANEDIOIC ACID
(2S)-2-[[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]-OXO-METHYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]GLUTARIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]CARBONYLAMINO]PENTANEDIOIC ACID
[<sup>3</sup>H]-folic acid
Acide folique
ácido fólico
Acidum folicum
ACIFOLIC
Apo-Folic
B03BB01
b9, Vitamin
BIO SCIENCE
CYTOFOL
DOSFOLAT B ACTIV
FOLACID
FOLACIN
FOLATE
FOLBAL
FOLCIDIN
FOLDINE
FOLETTES
FOLIAMIN
FOLIC ACID
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
FOLICARE
FOLICET
FOLIPAC
|
FOLSAEURE
FOLSAN
FOLSAURE
Folsäure
FOLSAV
FOLVITE
Folvron
INCAFOLIC
LEXPEC
LIVER LACTOBACILLUS CASEI FACTOR
MILLAFOL
N-(4-{[(2-AMINO-4-OXO-3,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}BENZOYL)-L-GLUTAMIC ACID
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)CARBONYL]-L-GLUTAMIC ACID
N-[4-[[(2-AMINO-3,4-DIHYDRO-4-OXO-6-PTERIDINYL)METHYL]AMINO]BENZOYL]-L-GLUTAMIC ACID
NATUR FLOW
N-Pteroyl-L-glutamate
N-PTEROYL-L-GLUTAMIC ACID
NSC-3073
PGA
PRECONCEIVE
PTEGLU
PTEROYLGLUTAMATE
PTEROYLGLUTAMIC ACID
PTEROYL-L-GLUTAMATE
PTEROYL-L-GLUTAMIC ACID
PTEROYL-L-MONOGLUTAMATE
PTEROYL-L-MONOGLUTAMIC ACID
PTEROYLMONOGLUTAMIC ACID
ROCHE
Vitamin B9
VITAMIN BC
VITAMIN BE
VITAMIN M
|
|
18 |
|
Raclopride |
Investigational |
Phase 4 |
|
84225-95-6 |
5118 3033769 |
Synonyms:
(-)-raclopride|<i>S</i>-(-)-raclopride|<i>S</i>-raclopride
[<sup>3</sup>H]-raclopride
3,5-Dichloro-N-[(1-ethylpyrrolidin-2-yl)methyl]-2-hydroxy-6-methoxybenzene-1-carboximidate
|
Racloprida
RACLOPRIDE
Raclopridum
|
|
19 |
|
Hormones |
|
Phase 4 |
|
|
|
20 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
21 |
|
Analgesics, Opioid |
|
Phase 4 |
|
|
|
22 |
|
Acidophilus |
|
Phase 4 |
|
|
|
23 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
24 |
|
Antidepressive Agents |
|
Phase 4 |
|
|
|
25 |
|
Serotonin Receptor Agonists |
|
Phase 4 |
|
|
|
26 |
|
Sympathomimetics |
|
Phase 4 |
|
|
|
27 |
|
Psychotropic Drugs |
|
Phase 4 |
|
|
|
28 |
|
Dopamine Antagonists |
|
Phase 4 |
|
|
|
29 |
|
Folate |
|
Phase 4 |
|
|
|
30 |
|
Vitamins |
|
Phase 4 |
|
|
|
31 |
|
Vitamin B9 |
|
Phase 4 |
|
|
|
32 |
|
Trace Elements |
|
Phase 4 |
|
|
|
33 |
|
Vitamin B Complex |
|
Phase 4 |
|
|
|
34 |
|
Hematinics |
|
Phase 4 |
|
|
|
35 |
|
Micronutrients |
|
Phase 4 |
|
|
|
36 |
|
Anti-Obesity Agents |
|
Phase 4 |
|
|
|
37 |
|
Hypoglycemic Agents |
|
Phase 4 |
|
|
|
38 |
|
Serotonin 5-HT1 Receptor Agonists |
|
Phase 4 |
|
|
|
39 |
|
Lipid Regulating Agents |
|
Phase 4 |
|
|
|
40 |
|
GABA Agonists |
|
Phase 4 |
|
|
|
41 |
|
Incretins |
|
Phase 4 |
|
|
|
42 |
|
Appetite Depressants |
|
Phase 4 |
|
|
|
43 |
|
Analgesics |
|
Phase 4 |
|
|
|
44 |
|
Antiparkinson Agents |
|
Phase 4 |
|
|
|
45 |
|
Serotonin and Noradrenaline Reuptake Inhibitors |
|
Phase 4 |
|
|
|
46 |
|
Excitatory Amino Acid Antagonists |
|
Phase 4 |
|
|
|
47 |
|
Contraceptive Agents |
|
Phase 4 |
|
|
|
48 |
|
glucocorticoids |
|
Phase 4 |
|
|
|
49 |
|
Contraceptives, Oral, Hormonal |
|
Phase 4 |
|
|
|
50 |
|
Contraceptives, Oral |
|
Phase 4 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 579)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Effect of Zinc Supplementation on Appetite and Growth of Primary Malnourished Children |
Unknown status |
NCT03098810 |
Phase 4 |
Zinc sulphate |
2 |
Effect of Early Oral Triple Viable Bifidobacterium Intestinal Flora in Preterm |
Completed |
NCT02060084 |
Phase 4 |
a control group;a probiotic-supplemented group |
3 |
Monoamine Contributions to Neurocircuitry in Eating Disorders |
Completed |
NCT02020408 |
Phase 4 |
[11C]raclopride;[11C]DASB;amphetamine |
4 |
Folic Acid Supplementation for Improving Homocysteine Levels, Cognitive and Depressive Status in Eating Disorders |
Completed |
NCT01493674 |
Phase 4 |
|
5 |
Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa |
Completed |
NCT00685334 |
Phase 4 |
Olanzapine;Aripiprazole |
6 |
Effectiveness of Psychological Treatments for BED |
Completed |
NCT00060762 |
Phase 4 |
|
7 |
Fluoxetine After Weight Restoration in Anorexia Nervosa |
Completed |
NCT00288574 |
Phase 4 |
Fluoxetine;Placebo |
8 |
A Double-blind, Placebo-controlled, Cross-over Study Using Baclofen in the Treatment of Rumination Syndrome |
Completed |
NCT03113396 |
Phase 4 |
Baclofen;Placebo oral capsule |
9 |
A 12-Week, Double-Blind, Placebo-Controlled, Trial of Duloxetine Versus Placebo in the Treatment of Binge Eating Disorder and Comorbid Depressive Disorder. |
Completed |
NCT00607789 |
Phase 4 |
Duloxetine;Placebo |
10 |
An Open-Label, Prospective Trial of Memantine in the Treatment of Moderate to Severe Binge Eating Disorder Associated With Obesity |
Completed |
NCT00330655 |
Phase 4 |
memantine |
11 |
Atomoxetine in the Treatment of Binge Eating Disorder: A Single-Center, Double-Blind, Placebo-Controlled, Flexible Dose Study in Outpatients |
Completed |
NCT00327834 |
Phase 4 |
atomoxetine |
12 |
Naltrexone: Consummatory Behaviors in Alcoholic Women |
Completed |
NCT00000448 |
Phase 4 |
naltrexone;Placebo |
13 |
Impact of Behavioral Feeding Intervention on Parent-Child Attachment in Young Children |
Completed |
NCT02187952 |
Phase 4 |
|
14 |
Evaluation of Splanchnic Oximetry,Doppler Flow Velocimetry in the Superior Mesenteric Artery and Feeding Tolerance in VERY LOW BIRTH WEIGHT IUGR and NON-IUGR Infants Receiving Bolus Versus Continuous Enteral Nutrition |
Completed |
NCT01341236 |
Phase 4 |
|
15 |
Controlled Trial of Orlistat With Behavioral Weight Loss Therapy for Obesity and Binge Eating in Monolingual Hispanic Persons |
Completed |
NCT00516919 |
Phase 4 |
Xenical + behavioral intervention |
16 |
Treatment of Binge Eating in Obese Patients in Primary Care |
Completed |
NCT00537810 |
Phase 4 |
Sibutramine;Placebo |
17 |
The Influence of Appetite-Related Central and Gut Hormones in Modulating Binge Eating Behaviour in Obese and Overweight Healthy Subjects |
Completed |
NCT01739049 |
Phase 4 |
Liraglutide |
18 |
Solriamfetol in Binge Eating Disorder |
Recruiting |
NCT04602936 |
Phase 4 |
Solriamfetol;Placebo |
19 |
iKanEat: A Randomized-controlled, Multi-center Trial of Megestrol for Chronic Oral Food Refusal in Children 9 Months to 9 Years 0 Months of Age |
Recruiting |
NCT03815019 |
Phase 4 |
Megestrol Acetate |
20 |
Effects of Cyproheptadine on Growth and Behavior in Pediatric Feeding Disorders |
Terminated |
NCT02568007 |
Phase 4 |
Cyproheptadine |
21 |
Hydroxyzine Effects on Meal-Related Anxiety in Underweight Adolescents and Young Adults Diagnosed With an Eating Disorder - A Pilot Study |
Withdrawn |
NCT01372670 |
Phase 4 |
Hydroxyzine;hydroxyzine HCL |
22 |
Feedback Versus no Feedback to Improve Patient Outcome in Group Psychotherapy for Eating Disorders: A Randomised Clinical Trial |
Unknown status |
NCT01693237 |
Phase 2, Phase 3 |
|
23 |
Clinical Controlled Trial on Extinction of Opioidergic Binge Eating Disorder (BED) With Intranasal Naloxone Administration |
Unknown status |
NCT01567670 |
Phase 2, Phase 3 |
Naloxone;naloxone placebo |
24 |
A Randomized, Double-Bind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study to Assess Efficacy and Safety of Rimonabant 20 mg Versus Placebo on Weight Loss and Frequency of Binge Episodes in Obese Patients With Food Craving |
Completed |
NCT00481975 |
Phase 3 |
rimonabant (SR141716) |
25 |
Effects of Oral Stimulation on Feeding Performance, Length of Hospital Stay and Anthropometric Variables of Preterm Infants |
Completed |
NCT03911674 |
Phase 3 |
|
26 |
Placebo-Controlled Trial of Bupropion for the Treatment of Binge Eating Disorder |
Completed |
NCT00414167 |
Phase 2, Phase 3 |
bupropion |
27 |
An Open-label, Flexibly-dosed, Multicenter, Extension Study of Dasotraline to Evaluate Long-term Safety and Tolerability in Adults With Binge-eating Disorder |
Completed |
NCT02684279 |
Phase 3 |
Dasotraline |
28 |
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder |
Completed |
NCT03107026 |
Phase 3 |
dasotraline 4mg;dasotraline 6mg;Placebo |
29 |
Effects of Denosumab on Bone Mineral Density, Markers of Bone Metabolism and Bone Microarchitecture in Women With Anorexia Nervosa: A Pilot Study |
Completed |
NCT03292146 |
Phase 3 |
Denosumab 60 MG [Prolia];Placebo Injection;Alendronate 70Mg Tab |
30 |
Deficits in Emotion Regulation Skills as a Maintaining Factor in Binge Eating Disorder |
Completed |
NCT03717493 |
Phase 2, Phase 3 |
|
31 |
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder |
Completed |
NCT02009163 |
Phase 3 |
Lisdexamfetamine dimesylate |
32 |
Acamprosate in the Treatment of Binge-Eating Disorder |
Completed |
NCT00511940 |
Phase 2, Phase 3 |
acamprosate |
33 |
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Examine the Efficacy and Safety of Meridia (Sibutramine Hydrochloride) in Binge-Eating Disorder |
Completed |
NCT00402584 |
Phase 3 |
sibutramine |
34 |
A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder |
Completed |
NCT02564588 |
Phase 2, Phase 3 |
Dasotraline;Placebo |
35 |
Sodium Oxybate in the Treatment of Binge Eating Disorder |
Completed |
NCT00514995 |
Phase 2, Phase 3 |
Sodium Oxybate |
36 |
Meditation-Based Treatment for Binge Eating Disorder |
Completed |
NCT00032760 |
Phase 2, Phase 3 |
|
37 |
Lisdexamfetamine in Binge Eating Disorder of Moderate or Greater Severity |
Completed |
NCT01090713 |
Phase 3 |
lisdexamfetamine;Placebo control |
38 |
A Phase 3, Multicenter, Open-label, 12 Month Extension Safety and Tolerability Study of SPD489 in the Treatment of Adults With Binge Eating Disorder |
Completed |
NCT01657019 |
Phase 3 |
Lisdexamfetamine dimesylate |
39 |
Randomized, Double-blind Placebo Controlled Trial With Topiramate for the Treatment of Obese Patients With Binge Eating Disorder |
Completed |
NCT00307619 |
Phase 3 |
topiramate |
40 |
Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity: A Single Center, Double-Blind, Placebo-controlled, Flexible-Dose Study in Outpatients |
Completed |
NCT00221442 |
Phase 3 |
Zonegran;sugar pill |
41 |
A Multicenter, Randomized, Double-blind, Placebo-controlled, Flexible-dose Study to Assess the Safety and Efficacy of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity |
Completed |
NCT00210808 |
Phase 2, Phase 3 |
topiramate |
42 |
Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity: A Single-Center, Double-Blind, Placebo-Controlled, Flexible-Dose Study in Outpatients |
Completed |
NCT00277641 |
Phase 3 |
Lamotrigine;placebo |
43 |
Armodafinil in Binge Eating Disorder (BED) |
Completed |
NCT01010789 |
Phase 3 |
Armodafinil;Matching placebo |
44 |
Diaphragmatic Breathing and Progressive Muscle Relaxation: Behavioral Interventions for Gastrointestinal Rumination |
Completed |
NCT01576302 |
Phase 3 |
|
45 |
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder |
Completed |
NCT01718509 |
Phase 3 |
SPD489 (Lisdexamfetamine dimesylate);Placebo |
46 |
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder |
Completed |
NCT01718483 |
Phase 3 |
SPD489 (Lisdexamfetamine dimesylate);Placebo |
47 |
Effects of Romosozumab on Bone Density, Markers of Bone Metabolism and Bone Microarchitecture in Women With Anorexia Nervosa: A Pilot Study |
Recruiting |
NCT04779216 |
Phase 3 |
Romosozumab Prefilled Syringe;Placebo;Alendronate 70Mg Tab |
48 |
Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity |
Recruiting |
NCT03926052 |
Phase 3 |
Lisdexamfetamine Dimesylate;Placebo |
49 |
Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity |
Recruiting |
NCT03924193 |
Phase 3 |
Lisdexamfetamine Dimesylate |
50 |
Cognitive-Behavioral and Pharmacologic Treatment of Binge-Eating Disorder and Obesity |
Recruiting |
NCT03946111 |
Phase 2, Phase 3 |
Naltrexone and Bupropion |
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
Paroxetine
Paroxetine Hydrochloride
|
Sertraline
Sertraline Hydrochloride
|
|